Zobrazeno 1 - 10
of 972
pro vyhledávání: '"Nicholas J Vogelzang"'
Autor:
Tian Zhang, Nicholas J Vogelzang, Daniel P Petrylak, Ravi A Madan, Karen A Autio, Ray Li, Helen Cho, Szu-Yu Tang, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Xin-Hua Zhu, Hani Babiker, Sandip M Prasad, Michael T Schweizer, Stephane Billotte, Nora Cavazos, Orlaith Bogg, Kam Chan, Megan Kaneda, I-Ming Wang, Jenny Zheng, Robert Hollingsworth, Kenneth A Kern
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background This phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR).Methods For dose escal
Externí odkaz:
https://doaj.org/article/a4a8a3a078ab4567a1641ae4c2b5d1db
Autor:
Patricia M LoRusso, Aleksandar Sekulic, Jeffrey A Sosman, Winnie S Liang, John Carpten, David W Craig, David B Solit, Alan H Bryce, Jeffrey A Kiefer, Jessica Aldrich, Sara Nasser, Rebecca Halperin, Sara A Byron, Mary Jo Pilat, Scott A Boerner, Diane Durecki, William P D Hendricks, Daniel Enriquez, Tyler Izatt, Jonathan Keats, Christophe Legendre, Svetomir N Markovic, Amy Weise, Fatima Naveed, Jessica Schmidt, Gargi D Basu, Shobana Sekar, Jonathan Adkins, Erica Tassone, Karthigayini Sivaprakasam, Victoria Zismann, Valerie S Calvert, Emanuel F Petricoin, Leslie Anne Fecher, Christopher Lao, J Paul Eder, Nicholas J Vogelzang, Jane Perlmutter, Mark Gorman, Barbara Manica, Lisa Fox, Nicholas Schork, Daniel Zelterman, Michelle DeVeaux, Richard W Joseph, C Lance Cowey, Jeffrey M Trent
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0248097 (2021)
Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted agents have been ineffective for BRAFV600wild-type (wt) metastatic melanomas. The SU2C Genomics-
Externí odkaz:
https://doaj.org/article/ea286e5ad5d3466fb04534c8639561db
Autor:
Bradford R Hirsch, John M Burke, Manish Agrawal, Ralph J Hauke, Thomas E Hutson, Gury Doshi, Mark T Fleming, Nicholas J Vogelzang
Publikováno v:
Journal of Kidney Cancer and VHL, Vol 3, Iss 1, Pp 23-35 (2016)
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade. As the number of available agents, and related volume of research, has grown, it is increasingly complex to know how to optimally treat patients. The
Externí odkaz:
https://doaj.org/article/d0df7e06ded845189cfe1511e28aaeab
Autor:
Mark A Moyad, Nicholas J Vogelzang
Publikováno v:
Asian Journal of Andrology, Vol 17, Iss 5, Pp 783-791 (2015)
Cardiovascular disease (CVD) has been the number one cause of death in the U.S. for 114 of the last 115 years. Lifestyle factors that promote CVD also appear to increase prostate cancer risk and those that reduce CVD risk also appear to reduce the ri
Externí odkaz:
https://doaj.org/article/ae4db668faa04b58a56e0553050a0ec4
Autor:
Sumanta K Pal, Nora Ruel, Sergio Villegas, Mark Chang, Kara DeWalt, Timothy G Wilson, Nicholas J Vogelzang, Bertram E Yuh
Publikováno v:
PLoS ONE, Vol 9, Iss 4, p e94471 (2014)
Clinical guidelines suggest neoadjuvant cisplatin-based chemotherapy prior to cystectomy in the setting of muscle-invasive bladder cancer (MIBC). A creatinine clearance (CrCl) >60 mL/min is frequently used to characterize cisplatin-eligible patients,
Externí odkaz:
https://doaj.org/article/8f944fe60e8048d883e9458a7d441200
Autor:
Alicia K. Morgans, Thomas Hutson, Alice Kai Dan Guan, David Garcia, Anna Zhou, Edward Drea, Nicholas J. Vogelzang
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Cabazitaxel significantly improves clinical outcomes compared with a second androgen receptor-targeted agent (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and an
Externí odkaz:
https://doaj.org/article/6d4b407f4b4b48b78c689dd2fe67da45
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Andrea Loehr, Arif Hussain, Akash Patnaik, Alan H. Bryce, Daniel Castellano, Albert Font, Jeremy Shapiro, Jingsong Zhang, Brieuc Sautois, Nicholas J. Vogelzang, Gurkamal Chatta, Kevin Courtney, Andrea Harzstark, Francesco Ricci, Darrin Despain, Simon Watkins, Charmin King, Minh Nguyen, Andrew D. Simmons, Simon Chowdhury, Wassim Abida
Publikováno v:
European Urology. 83:200-209
Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are approved in the USA for the treatment of patients with BRCA1 or BRCA2 (BRCA) mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC). BRCA reversion mutations are a k
Autor:
Neil J. Shah, Sneha D. Sura, Reshma Shinde, Junxin Shi, Puneet K. Singhal, Nicholas J. Robert, Nicholas J. Vogelzang, Rodolfo F. Perini, Robert J. Motzer
Publikováno v:
European Urology Open Science. 49:110-118
Autor:
Neeraj Agarwal, Catherine M. Tangen, Maha H.A. Hussain, Shilpa Gupta, Melissa Plets, Primo N. Lara, Andrea L. Harzstark, Przemyslaw W. Twardowski, Channing J. Paller, Dylan Zylla, Matthew R. Zibelman, Ellis Levine, Bruce J. Roth, Amir Goldkorn, Daniel A. Vaena, Manish Kohli, Tony Crispino, Nicholas J. Vogelzang, Ian M. Thompson, David I. Quinn
Publikováno v:
Journal of Clinical Oncology. 40:3301-3309
PURPOSE Orteronel (TAK-700) is a nonsteroidal 17,20-lyase inhibitor suppressing androgen synthesis. We evaluated the clinical benefit of orteronel when added to androgen deprivation therapy (ADT) in patients with newly diagnosed metastatic hormone-se